Abstract
Because atrial fibrillation (AF) is a major risk for thrombotic disease, many patients with AF are managed with anticoagulation for primary or secondary prevention of these events. The emergence of novel oral anticoagulants offers patients and providers options to consider beyond warfarin. Decision making should address safety, tolerability, efficacy, price, and simplicity of use; and decisions should be individualized for each patient.
MeSH terms
-
Aged
-
Aged, 80 and over
-
Anticoagulants / therapeutic use*
-
Atrial Fibrillation / complications*
-
Dabigatran / therapeutic use
-
Female
-
Humans
-
Male
-
Middle Aged
-
Pyrazoles / therapeutic use
-
Pyridines / therapeutic use
-
Pyridones / therapeutic use
-
Risk Factors
-
Rivaroxaban / therapeutic use
-
Stroke / etiology
-
Stroke / prevention & control
-
Thiazoles / therapeutic use
-
Thrombosis / etiology
-
Thrombosis / prevention & control*
Substances
-
Anticoagulants
-
Pyrazoles
-
Pyridines
-
Pyridones
-
Thiazoles
-
apixaban
-
Rivaroxaban
-
Dabigatran
-
edoxaban